Cue Biopharma, Inc.
CUE
$0.56
-$0.01-1.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -35.58% | 11.14% | -75.48% | -13.45% | 58.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.58% | 11.14% | -75.48% | -13.45% | 58.86% |
| Cost of Revenue | -42.03% | -17.00% | -17.77% | -27.46% | -91.75% |
| Gross Profit | -33.74% | 27.88% | 4.70% | 29.64% | 137.77% |
| SG&A Expenses | 47.04% | 4.78% | -0.26% | -29.27% | -17.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.86% | -11.13% | -11.57% | -27.69% | -9.40% |
| Operating Income | 15.35% | 16.84% | 2.91% | 29.59% | 21.95% |
| Income Before Tax | 14.00% | 16.61% | 0.73% | 29.31% | 21.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.00% | 16.61% | 0.73% | 29.31% | 21.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.00% | 16.61% | 0.73% | 29.31% | 21.31% |
| EBIT | 15.35% | 16.84% | 2.91% | 29.59% | 21.95% |
| EBITDA | 15.29% | 17.00% | 2.95% | 29.72% | 21.95% |
| EPS Basic | 56.33% | 56.14% | 33.85% | 55.06% | 28.81% |
| Normalized Basic EPS | 57.12% | 56.20% | 33.85% | 54.55% | 28.03% |
| EPS Diluted | 56.33% | 56.14% | 33.85% | 55.06% | 28.81% |
| Normalized Diluted EPS | 57.12% | 56.20% | 33.85% | 54.55% | 28.03% |
| Average Basic Shares Outstanding | 96.90% | 90.25% | 50.11% | 57.30% | 10.51% |
| Average Diluted Shares Outstanding | 96.90% | 90.25% | 50.11% | 57.30% | 10.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |